Roles for miRNAs in endocrine resistance in breast cancer

Endocrine-Related Cancer

Volumn 22, Issue 5, 2015, Pages R279-R300

  Muluhngwi, Penn ^a   Klinge, Carolyn M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Antiestrogen; Aromatase inhibitor; Breast cancer; Endocrine resistance; Estrogen receptor; MiRNA; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ARGONAUTE 2 PROTEIN; DICER; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; GROWTH FACTOR RECEPTOR; LETROZOLE; MICRORNA; MICRORNA 101; MICRORNA 126; MICRORNA 15A; MICRORNA 16; MICRORNA 200B; MICRORNA 200C; MICRORNA 210; MICRORNA 221; MICRORNA 222; MICRORNA 375; RALOXIFENE; RIBONUCLEASE III; TAMOXIFEN; TOREMIFENE;

APOPTOSIS; BIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; GENE TARGETING; HUMAN; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RNA TRANSPORT; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; PATHOLOGY;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MICRORNAS;

EID: 84942091400     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0355     Document Type: Review

References (192)

1. Acconcia F, Ascenzi P, Fabozzi G, Visca P & Marino M 2004 S-palmitoylation modulates human estrogen receptor-a functions. Biochemical and Biophysical Research Communications 316 878-883. (doi:10.1016/j.bbrc. 2004.02.129)
2. Adams BD, Claffey KP & White BA 2009 Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 150 14-23. (doi:10.1210/en.2008-0984)
3. Aiyer HS, Warri AM, Woode DR, Hilakivi-Clarke L & Clarke R 2012 Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention. Journal of Agricultural and Food Chemistry 60 5693-5708. (doi:10.1021/jf204084f)
4. Anbalagan M & Rowan BG 2015 Estrogen receptor a phosphorylation and its functional impact in human breast cancer. Molecular and Cellular Endocrinology [in press]. (doi:10.1016/j.mce.2015.01.016)
5. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan X-Y, Sauter G, Kallioniemi O-P, Trent JM & Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 965-968. (doi:10.1126/science.277.5328.965)
6. Arpino G, Wiechmann L, Osborne CK & Schiff R 2008 Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Reviews 29 217-233. (doi:10.1210/er. 2006-0045)
7. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B & Cheskis BJ 2004 Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Molecular Endocrinology 18 1096-1108. (doi:10.1210/me.2003-0335)
8. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 281-297. (doi:10.1016/S0092-8674(04)0045-5)
9. Baskerville S & Bartel DP 2005 Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11 241-247. (doi:10.1261/rna.7240905)
10. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC et al. 1983 Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2 450. (doi:10.1016/S0140-6736(83)0406-3)
11. Becker LE, Takwi AA, Lu Z & Li Y 2015 The role of miR-200a in mammalian epithelial cell transformation. Carcinogenesis 36 2-12. (doi:10.1093/carcin/bgu202)
12. Bedard PL, Freedman OC, Howell A & Clemons M 2008 Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Research and Treatment 108 307-317. (doi:10.1007/s10549-007-9606-8)
13. Bergamaschi A & Katzenellenbogen BS 2012 Tamoxifen downregulation of miR-451 increases 14-3-3z and promotes breast cancer cell survival and endocrine resistance. Oncogene 31 39-47. (doi:10.1038/onc.2011.223)
14. Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H & Katzenellenbogen BS 2014 The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Research 16 436. (doi:10.1186/s13058-014-0436-4)
15. Berillo O, Regnier M & Ivashchenko A 2013 Binding of intronic miRNAs to the mRNAs of host genes encoding intronic miRNAs and proteins that participate in tumourigenesis. Computers in Biology and Medicine 43 1374-1381. (doi:10.1016/j.compbiomed.2013.07.011)
16. Bohnsack MT, Czaplinski K & Gorlich D 2004 Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10 185-191. (doi:10.1261/rna.5167604)
17. Bradley JR & Pober JS 2001 Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20 6482-6491. (doi:10.1038/sj.onc.1204788)
18. Braicu C, Tomuleasa C, Monroig P, Cucuianu A, Berindan-Neagoe I & Calin GA 2015 Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death and Differentiation 22 34-45. (doi:10.1038/cdd.2014.130)
19. Brown DM & Ruoslahti E 2004 Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 5 365-374. (doi:10.1016/S1535-6108(04)0079-0)
20. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J et al. 2009 Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Research 69 1302-1313. (doi:10.1158/0008-5472.CAN-08-2741)
21. Chen WX, Zhong SL, Ji MH, Pan M, Hu Q, Lv MM, Luo Z, Zhao JH & Tang JH 2014a MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biology 35 2883-2892. (doi:10.1007/s13277-013-1417-4)
22. Chen WX, Cai YQ, Lv MM, Chen L, Zhong SL, Ma TF, Zhao JH & Tang JH 2014b Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour Biology 35 9649-9659. (doi:10.1007/s13277-014-2242-0)
23. Chen WX, Liu XM, Lv MM, Chen L, Zhao JH, Zhong SL, Ji MH, Hu Q, Luo Z, Wu JZ et al. 2014c Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS ONE 9 e95240. (doi:10.1371/journal.pone.0095240)
24. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K & Shiekhattar R 2005 TRBP recruits the Dicer complex to Ago2 formicroRNA processing and gene silencing. Nature 436 740-744. (doi:10.1038/nature03868)
25. Chiba M, Kimura M & Asari S 2012 Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. Oncology Reports 28 1551-1558. (doi:10.3892/or.2012.1967)
26. Choi HJ, Lui A, Ogony J, Jan R, Sims PJ & Lewis-Wambi J 2015 Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Research 17 6. (doi:10.1186/s13058-014-0506-7)
27. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME & Jones FE 2010a Oncogenic HER2{D}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31 2049-2057. (doi:10.1093/carcin/bgq192)
28. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD & Jones FE 2010b Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Molecular Cancer 9 317. (doi:10.1186/1476-4598-9-317)
29. Clark GM & McGuire WL 1988 Steroid receptors and other prognostic factors in primary breast cancer. Seminars in Oncology 15 20-25.
30. Clark GM, Osborne CK &McGuire WL 1984 Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. Journal of Clinical Oncology 2 1102-1109.
31. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y et al. 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22 7316-7339. (doi:10.1038/sj.onc.1206937)
32. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR & Jasani B 2001 Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. Journal of Immunological Methods 247 163-174. (doi:10.1016/S0022-1759(00)0321-5)
33. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D & Richer JK 2010 MicroRNAs link estrogen receptor a status and Dicer levels in breast cancer. Hormones & Cancer 1 306-319. (doi:10.1007/s12672-010-0043-5)
34. Colditz GA 1998 Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. Journal of the National Cancer Institute 90 814-823. (doi:10.1093/jnci/90.11.814)
35. Cortes-Sempere M & Ibanez de Caceres I 2011 microRNAs as novel epigenetic biomarkers for human cancer. Clinical & Translational Oncology 13 357-362. (doi:10.1007/s12094-011-0668-z)
36. Cui J, Bi M, Overstreet AM, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z et al. 2014 MiR-873 regulates ER[a] transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene 34 3895-3907. (doi:10.1038/onc.2014.430)
37. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF & Investigators AL 2010 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet. Oncology 11 1135-1141. (doi:10.1016/S1470-2045(10)70257-6)
38. Deng H, Yin L, Zhang XT, Liu LJ, Wang ML & Wang ZY 2014 ER-a variant ER-a36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells. Journal of Steroid Biochemistry and Molecular Biology 144 Pt B 417-426. (doi:10.1016/j.jsbmb.2014. 08.017)
39. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, KawamuraMJ & Wicha MS 2003 In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes and Development 17 1253-1270. (doi:10.1101/gad.1061803)
40. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M et al. 2010 Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology 28 509-518. (doi:10.1200/JCO.2009. 23.1274)
41. Doyle L & Ross DD 2003 Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 7340-7358. (doi:10.1038/sj.onc.1206938)
42. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467. (doi:10.1016/S0140-6736(97)1423-4)
43. Eichelser C, Stuckrath I, Muller V, Milde-Langosch K, Wikman H, Pantel K & Schwarzenbach H 2014 Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5 9650-9663.
44. Eissa S, Matboli M & Shehata HH 2015 Breast tissue-based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer. Translational Research 165 417-427. (doi:10.1016/j.trsl.2014.10.001)
45. Ferraro L, Ravo M, Nassa G, Tarallo R, De Filippo MR, Giurato G, Cirillo F, Stellato C, Silvestro S, Cantarella C et al. 2012 Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells. Hormones & Cancer 3 65-78. (doi:10.1007/s12672-012-0102-1)
46. Filardo EJ, Quinn JA & Sabo E 2008 Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 73 870-873. (doi:10.1016/j.steroids.2007.12.025)
47. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N et al. 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 117-120. (doi:10.1016/S0140-6736(89)1141-0)
48. Friedman RC, Farh KK, Burge CB & Bartel DP 2009 Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 19 92-105. (doi:10.1101/gr.082701.108)
49. Fukunaga R, Han BW, Hung JH, Xu J, Weng Z & Zamore PD 2012 Dicer partner proteins tune the length of mature miRNAs in flies and mammals. Cell 151 533-546. (doi:10.1016/j.cell.2012.09.027)
50. Gan R, Yang Y, Yang X, Zhao L, Lu J & Meng QH 2014 Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Therapy 21 290-296. (doi:10.1038/cgt.2014.29)
51. Gennarino VA, Sardiello M, Avellino R, Meola N, Maselli V, Anand S, Cutillo L, Ballabio A & Banfi S 2009 MicroRNA target prediction by expression analysis of host genes. Genome Research 19 481-490. (doi:10.1101/gr.084129.108)
52. Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, ChanMet al. 2015 microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biological Reviews of the Cambridge Philosophical Society [in press]. (doi:10.1111/brv.12176)
53. Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE & Bebawy M 2012 Microparticles and their emerging role in cancer multidrug resistance. Cancer Treatment Reviews 38 226-234. (doi:10.1016/j.ctrv.2011.06.005)
54. Gottardis MM, Robinson SP, Satyaswaroop PG & Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 48 812-815.
55. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP & White BA 2012 Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Research and Treatment 132 75-85. (doi:10.1007/s10549-011-1534-y)
56. Guzman N, Agarwal K, Asthagiri D, Saji M, Ringel MD & Paulaitis ME 2015 Breast cancer-specific miR signature unique to extracellular vesicles includes "microRNA-like" tRNA fragments. Molecular Cancer Research13 891-901. (doi:10.1158/1541-7786)
57. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q & Szallasi Z 2010 An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Research and Treatment 123 725-731. (doi:10.1007/s10549-009-0674-9)
58. Gyorffy B, Surowiak P, Budczies J& Lanczky A 2013 Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE 8 e82241. (doi:10.1371/journal.pone.0082241)
59. Han J, Lee Y, Yeom KH, Kim YK, Jin H & Kim VN 2004 The Drosha-DGCR8 complex in primary microRNA processing. Genes and Development 18 3016-3027. (doi:10.1101/gad.1262504)
60. Hasson SP, Rubinek T, Ryvo L & Wolf I 2013 Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway. Breast Care 8 248-255. (doi:10.1159/000354757)
61. Hayashi SI & Kimura M 2015 Mechanisms of hormonal therapy resistance in breast cancer. International Journal of Clinical Oncology 20 262-267. (doi:10.1007/s10147-015-0788-5)
62. Hayes EL & Lewis-Wambi JS 2015 Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Research 17 40. (doi:10.1186/s13058-015-0542-y)
63. He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R & Tang JH 2013 miR-342 is associated with estrogen receptor-a expression and response to tamoxifen in breast cancer. Experimental and Therapeutic Medicine 5 813-818. (doi:10.3892/etm.2013.915)
64. Herynk MH & Fuqua SA 2004 Estrogen receptor mutations in human disease. Endocrine Reviews 25 869-898. (doi:10.1210/er.2003-0010)
65. Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo WY, Schroth W & Brauch H 2013 Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. European Journal of Cancer 49 3598-3608. (doi:10.1016/j.ejca.2013.07.145)
66. Hossain A, Kuo MT & Saunders GF 2006 Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Molecular and Cellular Biology 26 8191-8201. (doi:10.1128/MCB.00242-06)
67. Howe EN, Cochrane DR & Richer JK 2012 The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. Journal of Mammary Gland Biology and Neoplasia 17 65-77. (doi:10.1007/s10911-012-9244-6)
68. Huntzinger E & Izaurralde E 2011 Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nature Reviews. Genetics 12 99-110. (doi:10.1038/nrg2936)
69. Hurteau GJ, Carlson JA, Spivack SD & Brock GJ 2007 Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Research 67 7972-7976. (doi:10.1158/0008-5472.CAN-07-1058)
70. Huynh FC & Jones FE 2014 MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2D16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS ONE 9 e114419. (doi:10.1371/journal.pone.0114419)
71. Iorio MV & Croce CM 2012 microRNA involvement in human cancer. Carcinogenesis 33 1126-1133. (doi:10.1093/carcin/bgs140)
72. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M et al. 2005 MicroRNA gene expression deregulation in human breast cancer. Cancer Research 65 7065-7070. (doi:10.1158/0008-5472.CAN-05-1783)
73. Jiang HL, Yu H, Ma X, Xu D, Lin GF, Ma DY & Jin JZ 2014 MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells. Tumour Biology 35 6955-6960. (doi:10.1007/s13277-014-1933-x)
74. Johnston SR 2010 New strategies in estrogen receptor-positive breast cancer. Clinical Cancer Research 16 1979-1987. (doi:10.1158/1078-0432.CCR-09-1823)
75. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M & Benz CC 1999 Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clinical Cancer Research 5 251-256.
76. Johnston SR, Martin LA, Head J, Smith I & Dowsett M 2005 Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. Journal of Steroid Biochemistry and Molecular Biology 95 173-181. (doi:10.1016/j. jsbmb.2005.04.004)
77. Johnstone RM, Adam M, Hammond JR, Orr L & Turbide C 1987 Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). Journal of Biological Chemistry 262 9412-9420.
78. Jordan VC & Brodie AM 2007 Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 7-25. (doi:10.1016/j.steroids.2006.10.009)
79. Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H & Brauch H 2011 The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant antihormone therapy: consequences and opportunities. Breast 20 (Suppl 3) S1-S11. (doi:10.1016/S0960-9776(11)0287-9)
80. Jordan VC, McDaniel R, Agboke F & Maximov PY 2014 The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. Steroids 90 3-12. (doi:10.1016/j.steroids.2014.06.009)
81. Jordan VC, Curpan R & Maximov PY 2015 Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. Journal of the National Cancer Institute 107 djv075. (doi:10.1093/jnci/djv075)
82. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST et al. 2012 Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118 2603-2614. (doi:10.1002/cncr.26565)
83. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Guckel B, Fehm T, Schneeweiss A et al. 2011 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-b signaling pathways. Oncogene 31 4150-4163. (doi:10.1038/onc.2011.571)
84. Khoshnaw SM, Rakha EA, Abdel-Fatah TM, Nolan CC, Hodi Z, Macmillan DR, Ellis IO & Green AR 2012 Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Research and Treatment 135 403-413. (doi:10.1007/s10549-012-2169-3)
85. Khoshnaw SM, Rakha EA, Abdel-Fatah T, Nolan CC, Hodi Z, Macmillan RD, Ellis IO & Green AR 2013 The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. Breast Cancer Research and Treatment 137 139-153. (doi:10.1007/s10549-012-2358-0)
86. Kim VN, Han J & Siomi MC 2009 Biogenesis of small RNAs in animals. Nature Reviews. Molecular Cell Biology 10 126-139. (doi:10.1038/nrm2632)
87. King HW, Michael MZ & Gleadle JM 2012 Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 12 421. (doi:10.1186/1471-2407-12-421)
88. Klinge CM 2012 miRNAs and estrogen action. Trends in Endocrinology and Metabolism 23 223-233. (doi:10.1016/j.tem.2012.03.002)
89. Klinge CM 2015 miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. Molecular and Cellular Endocrinology [in press]. (doi:10.1016/j.mce.2015.01.035)
90. Kozomara A & Griffiths-Jones S 2014 miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research 42 D68-D73. (doi:10.1093/nar/gkt1181)
91. Kruger S, Elmageed ZY, Hawke DH, Wörner PM, Jansen DA, Abdel-Mageed AB, Alt EU & Izadpanah R 2014 Molecular characterization of exosome-like vesicles from breast cancer cells. BMC Cancer 14 44. (doi:10.1186/1471-2407-14-44)
92. Lamouille S, Xu J & Derynck R 2014 Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews. Molecular Cell Biology 15 178-196. (doi:10.1038/nrm3758)
93. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J et al. 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. PNAS 95 2920-2925. (doi:10.1073/pnas.95.6.2920)
94. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, Kim YG, Jang JY & Kim CW 2013 Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS ONE 8 e84256. (doi:10.1371/journal.pone. 0084256)
95. Levin ER 2014 Extranuclear estrogen receptor's roles in physiology: lessons from mouse models. American Journal of Physiology. Endocrinology and Metabolism 307 E133-E140. (doi:10.1152/ajpendo.00626.2013)
96. Li L, Haynes MP & Bender JR 2003 Plasma membrane localization and function of the estrogen receptor a variant (ER46) in human endothelial cells. PNAS 100 4807-4812. (doi:10.1073/pnas. 0831079100)
97. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C et al. 2013a Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports 4 1116-1130. (doi:10.1016/j.celrep.2013.08.022)
98. Li G, Zhang J, Jin K, He K, Zheng Y, Xu X,Wang H, Wang H, Li Z, Yu X et al. 2013b Estrogen receptor-a36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Molecular Oncology 7 611-624. (doi:10.1016/j.molonc. 2013.02.001)
99. Li Q, Eades G, Yao Y, Zhang Y & Zhou Q 2014 Characterization of a stemlike subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions. Journal of Biological Chemistry 289 1303-1312. (doi:10.1074/jbc.M113. 502278)
100. Liao L, Kuang SQ, Yuan Y, Gonzalez SM, O'Malley BW & Xu J 2002 Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. Journal of Steroid Biochemistry and Molecular Biology 83 3-14. (doi:10.1016/S0960-0760 (02)0254-6)
101. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A & Riegel AT 2001 Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. Journal of Biological Chemistry 276 23763-23768. (doi:10.1074/jbc.M102397200)
102. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA et al. 2005 MicroRNA expression profiles classify human cancers. Nature 435 834-838. (doi:10.1038/nature03702)
103. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, Jacob ST & Majumder S 2011 Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. Journal of Biological Chemistry 286 42292-42302. (doi:10.1074/jbc. M111.270926)
104. Macias S, Cordiner RA & Caceres JF 2013 Cellular functions of the microprocessor. Biochemical Society Transactions 41 838-843. (doi:10.1042/BST20130011)
105. Manavalan TT, Teng Y, Appana SN, Datta S, Kalbfleisch TS, Li Y & Klinge CM 2011 Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Letters 313 26-43. (doi:10.1016/j.canlet. 2011.08.018)
106. Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N & Klinge CM 2013 Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS ONE 8 e62334. (doi:10.1371/journal.pone.0062334)
107. Mandlekar S & Kong AN 2001 Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 469-477. (doi:10.1023/A:1012437607881)
108. Marsico A, Huska MR, Lasserre J, Hu H, Vucicevic D, Musahl A, Orom UA & Vingron M 2013 PROmiRNA: a new miRNA promoter recognition method uncovers the complex regulation of intronic miRNAs. Genome Biology 14 R84. (doi:10.1186/gb-2013-14-8-r84)
109. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T et al. 2010 A microRNA targeting dicer for metastasis control. Cell 141 1195-1207. (doi:10.1016/j.cell.2010.05.017)
110. Martinez-Galan J, Torres-Torres B, Nunez MI, Lopez-Penalver J, Del Moral R, Ruiz De Almodovar JM, Menjon S, Concha A, Chamorro C, Rios S et al. 2014 ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer 14 59. (doi:10.1186/1471-2407-14-59)
111. Masri S, Liu Z, Phung S, Wang E, Yuan Y-C & Chen S 2010 The role of microRNA-128a in regulating TGFb signaling in letrozole-resistant breast cancer cells. Breast Cancer Research and Treatment 124 89-99. (doi:10.1007/s10549-009-0716-3)
112. McGuire A, Brown JA & Kerin MJ 2015 Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Reviews 34 145-155. (doi:10.1007/s10555-015-9551-7)
113. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G & Tuschl T 2004 Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Molecular Cell 15 185-197. (doi:10.1016/j.molcel. 2004.07.007)
114. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA et al. 2014 Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26 707-721. (doi:10.1016/j.ccell.2014.09.005)
115. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S & Majumder S 2008 MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. Journal of Biological Chemistry 283 29897-29903. (doi:10.1074/jbc.M804612200)
116. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E & Jones FE 2009 An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Molecular Cancer Therapeutics 8 2152-2162. (doi:10.1158/1535-7163.MCT-09-0295)
117. Moore MJ, Zhang C, Gantman EC, Mele A, Darnell JC & Darnell RB 2014 Mapping Argonaute and conventional RNA-binding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. Nature Protocols 9 263-293. (doi:10.1038/nprot. 2014.012)
118. Musgrove EA & Sutherland RL 2009 Biological determinants of endocrine resistance in breast cancer. Nature Reviews. Cancer 9 631-643. (doi:10.1038/nrc2713)
119. Nagaraj G & Ma C 2015 Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment 150 231-242. (doi:10.1007/s10549-015-3316-4)
120. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R & Vadlamudi RK 2004 Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Research 64 6416-6423. (doi:10.1158/0008-5472.CAN-04-1786)
121. Narayanan R, Jiang J, Gusev Y, Jones A, Kearbey JD, Miller DD, Schmittgen TD & Dalton JT 2010 MicroRNAs are mediators of androgen action in prostate and muscle. PLoS ONE 5 e13637. (doi:10.1371/journal.pone. 0013637)
122. Negrini M & Calin GA 2008 Breast cancer metastasis: a microRNA story. Breast Cancer Research 10 203. (doi:10.1186/bcr1867)
123. O'Brien CS, Howell SJ, Farnie G & Clarke RB 2009 Resistance to endocrine therapy: are breast cancer stem cells the culprits? Journal of Mammary Gland Biology and Neoplasia 14 45-54. (doi:10.1007/s10911-009-9115-y)
124. O'Day E & Lal A 2010 MicroRNAs and their target gene networks in breast cancer. Breast Cancer Research 12 201. (doi:10.1186/bcr2484)
125. Osborne CK & Schiff R 2011 Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine 62 233-247. (doi:10.1146/annurevmed-070909-182917)
126. Palma J, Yaddanapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML & Duelli DM 2012 MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Research 40 9125-9138. (doi:10.1093/nar/gks656)
127. Palmieri C, Patten DK, Januszewski A, Zucchini G & Howell SJ 2014 Breast cancer: current and future endocrine therapies. Molecular and Cellular Endocrinology 382 695-723. (doi:10.1016/j.mce.2013.08.001)
128. Park IH, Kang JH, Lee KS, Nam S, Ro J & Kim JH 2014 Identification and clinical implications of circulating microRNAs for estrogen receptorpositive breast cancer. Tumour Biology 35 12173-12180. (doi:10.1007/s13277-014-2525-5)
129. Perey L, Paridaens R, Hawle H, Zaman K, Nole F, Wildiers H, Fiche M, Dietrich D, Clement P, Koberle D et al. 2007 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Annals of Oncology 18 64-69. (doi:10.1093/annonc/mdl341)
130. Petz LN, Ziegler YS, Loven MA & Nardulli AM 2002 Estrogen receptor a and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 143 4583-4591. (doi:10.1210/en.2002-220369)
131. Pigati L, Yaddanapudi SC, Iyengar R, Kim D-J, Hearn SA, Danforth D, Hastings ML & Duelli DM 2010 Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE 5 e13515. (doi:10.1371/journal.pone.0013515)
132. Pradhan M, Bembinster LA, Baumgarten SC & Frasor J 2010 Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{k}B cooperativity at adjacent response elements. Journal of Biological Chemistry 285 31100-31106. (doi:10.1074/jbc.M110.155309)
133. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR & Vadlamudi RK 2007 Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Research 67 5505-5512. (doi:10.1158/0008-5472.CAN-06-3647)
134. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM & Nephew KP 2011 MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30 1082-1097. (doi:10.1038/onc.2010.487)
135. Razandi M, Pedram A, Park ST & Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. Journal of Biological Chemistry 278 2701-2712. (doi:10.1074/jbc.M205692200)
136. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A et al. 2011 Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet. Oncology 12 1101-1108. (doi:10.1016/S1470-2045 (11)0270-4)
137. Renoir J-M, Marsaud V & Lazennec G 2013 Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochemical Pharmacology 85 449-465. (doi:10.1016/j.bcp.2012.10.018)
138. Riggins RB, Bouton AH, Liu MC & Clarke R 2005 Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitamins and Hormones 71 201-237. (doi:10.1016/S0083-6729(05)1007-4)
139. Ring A & Dowsett M 2004 Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 11 643-658. (doi:10.1677/erc.1.00776)
140. Robinson DR,Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L et al. 2013 Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature Genetics 45 1446-1451. (doi:10.1038/ng.2823)
141. Rodriguez A, Griffiths-Jones S, Ashurst JL & Bradley A 2004 Identification of mammalian microRNA host genes and transcription units. Genome Research 14 1902-1910. (doi:10.1101/gr.2722704)
142. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW & Foekens JA 2011 MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Research and Treatment 127 43-51. (doi:10.1007/s10549-010-0940-x)
143. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A et al. 2008 MicroRNAs accurately identify cancer tissue origin. Nature Biotechnology 26 462-469. (doi:10.1038/nbt1392)
144. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL et al. 2011 Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 6 e20980. (doi:10.1371/journal.pone. 0020980)
145. Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L & Vadlamudi RK 2012 Significance of PELP1 in ER-negative breast cancer metastasis. Molecular Cancer Research 10 25-33. (doi:10.1158/1541-7786.MCR-11-0456)
146. Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun L, Tekmal RR & Vadlamudi RK 2014 Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene 33 3707-3716. (doi:10.1038/onc.2013.332)
147. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V & Mo YY 2011 MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene 30 822-831. (doi:10.1038/onc.2010.463)
148. Sanders DA, Ross-Innes CS, Beraldi D, Carroll JS & Balasubramanian S 2013 Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor a in breast cancer cells. Genome Biology 14 R6. (doi:10.1186/gb-2013-14-1-r6)
149. Santen RJ, Brodie H, Simpson ER, Siiteri PK & Brodie A 2009 History of aromatase: saga of an important biological mediator and therapeutic target. Endocrine Reviews 30 343-375. (doi:10.1210/er.2008-0016)
150. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC et al. 2000 Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. Journal of the National Cancer Institute 92 1926-1934. (doi:10.1093/jnci/92.23.1926)
151. van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY & Van Laere SJ 2015 Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Research 17 21. (doi:10.1186/s13058-015-0526-y)
152. Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A et al. 2011 Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clinical Cancer Research 17 6510-6521. (doi:10.1158/1078-0432.CCR-11-1403)
153. Sentis S, Le Romancer M, Bianchin C, Rostan MC & Corbo L 2005 Sumoylation of the estrogen receptor a hinge region regulates its transcriptional activity. Molecular Endocrinology 19 2671-2684. (doi:10.1210/me.2005-0042)
154. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B et al. 2009 Expression of ER-{a}36, a novel variant of estrogen receptor {a}, and resistance to tamoxifen treatment in breast cancer. Journal of Clinical Oncology 27 3423-3429. (doi:10.1200/JCO.2008.17.2254)
155. ShiW, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N et al. 2011 MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Research 71 2926-2937. (doi:10.1158/0008-5472.CAN-10-3369)
156. Simpson RJ, LimJW,Moritz RL &Mathivanan S 2009 Exosomes: proteomic insights and diagnostic potential. Expert Review of Proteomics 6 267-283. (doi:10.1586/epr.09.17)
157. Singh R & Mo Y-Y 2013 Role of microRNAs in breast cancer. Cancer Biology & Therapy 14 201-212. (doi:10.4161/cbt.23296)
158. Singh A & Settleman J 2010 EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29 4741-4751. (doi:10.1038/onc.2010.215)
159. Singh R, Pochampally R, Watabe K, Lu Z &Mo Y-Y 2014 Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Molecular Cancer 13 256. (doi:10.1186/1476-4598-13-256)
160. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM & Breakefield XO 2008 Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology 10 1470-1476. (doi:10.1038/ncb1800)
161. Smith GL 2014 The long and short of tamoxifen therapy: a review of the ATLAS trial. Journal of the Advanced Practitioner in Oncology 5 57-60.
162. Song GQ & Zhao Y 2015 MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration. Tumour Biology 36 5001-5009. (doi:10.1007/s13277-015-3151-6)
163. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
164. Steinestel K, Eder S, Schrader AJ & Steinestel J 2014 Clinical significance of epithelial-mesenchymal transition. Clinical and Translational Medicine 3 17. (doi:10.1186/2001-1326-3-17)
165. Stern H, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I & Eiermann W 2015 PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance. Clinical Cancer Research 21 2065-2074. (doi:10.1158/1078-0432.CCR-14-2993)
166. Subramani T, Yeap SK, Ho WY, Ho CL, Osman CP, Ismail NH, Rahman NM & Alitheen NB 2015 Nordamnacanthal potentiates the cytotoxic effects of tamoxifen in human breast cancer cells. Oncology Letters 9 335-340. (doi:10.3892/ol.2014.2697)
167. Thomas C & Gustafsson JA 2011 The different roles of ER subtypes in cancer biology and therapy. Nature Reviews. Cancer 11 597-608. (doi:10.1038/nrc3093)
168. Tien JC & Xu J 2012 Steroid receptor coactivator-3 as a potential molecular target for cancer therapy. Expert Opinion on Therapeutic Targets 16 1085-1096. (doi:10.1517/14728222.2012.718330)
169. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA et al. 2013 ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics 45 1439-1445. (doi:10.1038/ng.2822)
170. Ujihira T, Ikeda K, Suzuki T, Yamaga R, Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K et al. 2015 MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer. Scientific Reports 5 7641. (doi:10.1038/srep07641)
171. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A & Kumar R 2001 Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor a. Journal of Biological Chemistry 276 38272-38279. (doi:10.1074/jbc.M103783200)
172. Vadlamudi RK, Manavathi B, Balasenthil S, Nair SS, Yang Z, Sahin AA & Kumar R 2005 Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Research 65 7724-7732. (doi:10.1158/0008-5472.CAN-05-0614)
173. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ & Lotvall JO 2007 Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology 9 654-659. (doi:10.1038/ncb1596)
174. Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA & Cohen PA 2015 MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Research 17 13. (doi:10.1186/s13058-015-0515-1)
175. Wajant H, Pfizenmaier K & Scheurich P 2003 Tumor necrosis factor signaling. Cell Death and Differentiation 10 45-65. (doi:10.1038/sj.cdd. 4401189)
176. Wang CY, Mayo MW, Korneluk RG, Goeddel DV & Baldwin AS Jr 1998 NFkB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 1680-1683. (doi:10.1126/science.281.5383.1680)
177. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y & Deuel TF 2006 A variant of estrogen receptor-{a}, hER-{a}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. PNAS 103 9063-9068. (doi:10.1073/pnas.0603339103)
178. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T, Wiemann S & Sahin O 2013 Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 32 1173-1182. (doi:10.1038/onc. 2012.128)
179. Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin Ö& Wiemann S 2014 MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ERC breast cancer. Journal of Pathology 233 368-379. (doi:10.1002/path.4363)
180. Watson CS, Jeng YJ, Hu G, Wozniak A, Bulayeva N & Guptarak J 2012 Estrogen- and xenoestrogen-induced ERK signaling in pituitary tumor cells involves estrogen receptor-a interactions with G protein-ai and caveolin I. Steroids 77 424-432. (doi:10.1016/j.steroids. 2011.12.025)
181. Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, Li H, Zhu X, Yao L & Zhang J 2014 Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Research and Treatment 147 423-431. (doi:10.1007/s10549-014-3037-0)
182. Weng L, Ziliak D, Lacroix B, Geeleher P & Huang RS 2014 Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS ONE 9 e93420. (doi:10.1371/journal.pone.0093420)
183. Wiemer EA 2007 The role of microRNAs in cancer: no small matter. European Journal of Cancer 43 1529-1544. (doi:10.1016/j.ejca.2007. 04.002)
184. Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y, Hammond SM, Kim S & Nephew KP 2009 Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25 430-434. (doi:10.1093/bioinformatics/btn646)
185. Yang S & Lai EC 2011 Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Molecular Cell 43 892-903. (doi:10.1016/j.molcel.2011.07.024)
186. Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD & Song E 2011 Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular Cancer 10 117. (doi:10.1186/1476-4598-10-117)
187. Zhang X, Ding L, Kang L & Wang ZY 2012 Estrogen receptor-a36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS ONE 7 e30174. (doi:10.1371/journal.pone.0030174)
188. Zhang X, Tanaka K, Yan J, Li J, Peng D, Jiang Y, Yang Z, Barton MC, Wen H & Shi X 2013 Regulation of estrogen receptor a by histone methyltransferase SMYD2-mediated protein methylation. PNAS 110 17284-17289. (doi:10.1073/pnas.1307959110)
189. Zhao M & Ramaswamy B 2014 Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World Journal of Clinical Oncology 5 248-262. (doi:10.5306/wjco.v5.i3.248)
190. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D & Cheng JQ 2008 MicroRNA-221/222 negatively regulates estrogen receptor a and is associated with tamoxifen resistance in breast cancer. Journal of Biological Chemistry 283 31079-31086. (doi:10.1074/jbc. M806041200)
191. Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, Recker RR, Gatalica Z, Wang Z & Xiao GG 2011 let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor a signaling in breast cancer. Molecular Medicine 17 1233-1241. (doi:10.2119/molmed.2010.00225)
192. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S & Benz CC 2007 Enhanced NFkB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7 59. (doi:10.1186/1471-2407-7-59)